Why Mohs Sees the Whole Margin: Bread-Loafing vs. Complete Circumferential Assessment, Explained

Ask most patients why Mohs micrographic surgery has higher reported cure rates than standard excision for many skin cancers, and you will hear answers about precision, skill, or the surgeon checking the tissue on site. Those things matter, but they are downstream of a more fundamental difference: how the removed tissue is sliced before anyone looks at it under a microscope. This is a story about geometry, and it explains most of what makes Mohs distinct.

How standard excision tissue is examined. When a skin cancer is removed by conventional excision, the specimen is typically sent to an outside laboratory and processed with a technique often called bread-loafing. The tissue is cut vertically at intervals, usually every 2 to 4 millimeters, the way you would slice a loaf of bread. A pathologist then examines those cross sections. This is efficient and works well for many purposes, but it has a built-in blind spot: everything between the slices goes unexamined. Depending on slice spacing and specimen size, bread-loafing samples somewhere in the range of 1 to 2 percent of the true surgical margin. If a tumor sends out a narrow finger of cells that happens to fall between two slices, the pathologist can honestly report clear margins while cancer remains in the patient.

How Mohs tissue is examined. In Mohs surgery, the excised tissue is processed en face, meaning the entire undersurface and outer edge of the specimen are flattened into a single plane and sectioned horizontally. Conceptually, instead of slicing the loaf, you are looking at the entire bottom crust at once. This allows the surgeon, who also acts as the pathologist in this setting, to evaluate close to 100 percent of the peripheral and deep margin. If tumor appears anywhere on that margin, the surgeon marks its exact location on a map of the wound, returns to the patient, and removes another thin layer only where the tumor was seen. The cycle repeats until the margin is clear.

Why this matters most for certain tumors. The geometric advantage is largest when tumors grow unpredictably. Infiltrative and morpheaform basal cell carcinomas, recurrent tumors, and cancers on the nose, ears, eyelids, and lips are notorious for subclinical extension, meaning tumor that spreads beyond what is visible on the skin surface. These finger-like projections are exactly the structures bread-loafing can miss. This is why appropriate use criteria developed by dermatology and surgery organizations prioritize Mohs for high-risk anatomic sites, aggressive histologic subtypes, and recurrences, rather than recommending it for every skin cancer everywhere on the body. A small nodular basal cell carcinoma on the trunk, for example, is often treated perfectly well with standard excision.

The frozen section question. A common point of confusion: Mohs uses frozen sections, and frozen sections are sometimes described as lower quality than the permanent paraffin sections used in conventional pathology. That is partly true. Freezing can introduce artifacts, and certain diagnoses, particularly some melanomas, can be harder to interpret on frozen tissue. But the cure rate advantage of Mohs does not come from the freezing. Freezing is simply what makes same-day, layer-by-layer examination practical. The advantage comes from the en face orientation and complete margin visualization. Some practices now combine Mohs technique with immunostains such as MART-1 to improve frozen section interpretation for melanoma in situ, and some centers use a staged excision variant with permanent sections, sometimes called slow Mohs, which keeps the complete margin assessment while trading same-day results for paraffin-quality histology.

What complete margin control does not do. It is worth being clear about limits. Mohs evaluates the margin of what was removed. It cannot detect skip lesions that are truly discontinuous from the main tumor, it does not assess lymph nodes, and it does not change the biology of an aggressive cancer. Reported five-year cure rates of roughly 97 to 99 percent for primary basal cell carcinoma, and somewhat lower for recurrent tumors, reflect margin control, not immunity from recurrence.

The practical takeaway. If you are weighing Mohs against standard excision, the honest framing is not that one is good and the other is bad. It is that they answer different questions. Bread-loafing asks: is tumor present in these representative slices? En face processing asks: is tumor present anywhere on this entire margin? For high-risk tumors in tissue-critical locations, the second question is the one you want answered before the wound is closed. For low-risk tumors in forgiving locations, the first question is usually sufficient, faster, and less resource-intensive. Understanding the geometry helps patients ask better questions and helps clinicians explain their recommendations without overselling either approach.